Beyond chemotherapy, PARP inhibitors such as olaparib and rucaparib showed favorable outcomes during the maintenance therapy for patients with advanced ovarian cancer [23]; however, PARP inhibitors are only approved and effective for patients with BRCA1/2 mutation, which accounts for less than 40% of ovarian cancer cases [24]. This evidence concerns the gene BRCA1 and ovarian cancer.